Biomarkers for Alzheimer’s Disease and Parkinson’s Disease

  • John H. Growdon
  • Michael C. Irizarry
  • Clemens Scherzer
Part of the Advances in Behavioral Biology book series (ABBI, volume 57)


Mild Cognitive Impairment Lewy Body Disease Total Homocysteine Level Cortical Lewy Body Nondemented Control 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Consensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer’s Disease. Neurobiol Aging 1998;19:109–116CrossRefGoogle Scholar
  2. 2.
    Kantarci K, Clifford RJ. Quantitative magnetic resonance techniques as surrogate markers of Alzheimer’s disease. NeuroRx 2004;1:196–205PubMedCrossRefGoogle Scholar
  3. 3.
    Jagust W. Molecular neuroimaging in Alzheimer’s disease. NeuroRx 2004;1:206–212PubMedCrossRefGoogle Scholar
  4. 4.
    Brooks DJ. Neuroimaging in Parkinson’s disease NeuroRx 2004;1:243–254Google Scholar
  5. 5.
    Selkoe DJ. Alzheimer’s disease: genotypes, phenotypes and treatments. Science 1997;271:630–631CrossRefGoogle Scholar
  6. 6.
    Spillantini MG, Schmidt MI, Lee MY, et al. α-Synuclein in Lewy bodies. Nature 1997;388:839–840PubMedCrossRefGoogle Scholar
  7. 7.
    Irizarry M, Growdon W, Gomez-Isla T, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson’s disease and cortical Lewy body disease contain α-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998;57:334–337PubMedCrossRefGoogle Scholar
  8. 8.
    Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;4:601–607CrossRefGoogle Scholar
  9. 9.
    Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx 2004;1:213–225PubMedCrossRefGoogle Scholar
  10. 10.
    Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 1996;2:864–870PubMedCrossRefGoogle Scholar
  11. 11.
    Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid beta-peptide 1–42 and incipient Alzheimer’s disease. Ann Neurol 1999;46:412–416PubMedCrossRefGoogle Scholar
  12. 12.
    Fukumoto H, Tennis M, Locascio J, et al. Age but not diagnosis is the main predictor of plasma amyloid β-protein levels. Arch Neurol 2003;60:958–964PubMedCrossRefGoogle Scholar
  13. 13.
    O’Suilleabhain PE, Bottiglieri T, Dewey RB, et al. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson’s disease. Mov Disord 2004;19:1403–1408.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • John H. Growdon
    • 1
  • Michael C. Irizarry
  • Clemens Scherzer
  1. 1.Department of NeurologyPartners HealthCare System, Inc.BostonUSA

Personalised recommendations